Anti-PCSK9 (Evolocumab), Human IgG2 Antibody

Anti-PCSK9 (Evolocumab), Human IgG2 Antibodyis available at Gentaur for Next week Delivery.

Description: The research-grade biosimilar is a human IgG2 monoclonal antibody that is directed against proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 is a serine protease that binds to LDL receptors on the hepatocyte cell surface and promotes the lysosome-mediated degradation of these receptors. This results in decreased uptake and clearance of LDL-C (bad cholesterol) by the receptors. The monoclonal antibody binds to PCSK9 and prevents interaction with the LDL receptor. This promotes the recycling of the internalized LDL receptor to the hepatocyte cell surface and increased removal of LDL-C from the blood. The original drug received approval from the FDA to treat homozygous and heterozygous familial cholesterolemia. The drug has also been approved to treat patients with high cholesterol, whose LDL-C was not controlled by the statin treatment.

Immunogen Sequence:Human PCSK9

Target Alternative Name:AMG-145, AMG145, NN7415, FH3, PC9, FHCL3, NARC1, LDLCQ1, NARC-1, HCHOLA3

Species Reactivities:Human

Tag Line:The biosimilar is a human monoclonal antibody that targets PCSK9 and inhibits the binding with LDL receptors on the hepatocyte cell surface and promotes the clearance of LDL-C from the blood

Formulation:In PBS, pH 7.5

Purification: Protein A purified

Application:/

Positive Control:/

Application And Usages:/

Handling:The antibody solution should be gently mixed before use.